AAPL333.08+0.81 (+0.24%) ▲|ABBV261.77+4.65 (+1.81%) ▲|ABT103.09+1.14 (+1.12%) ▲|ACN195.00+11.10 (+6.04%) ▲|ADBE265.60+13.37 (+5.30%) ▲|AMAT424.21-32.28 (-7.07%) ▼|AMD493.41-22.72 (-4.40%) ▼|AMGN381.50+4.15 (+1.10%) ▲|AMT176.94-0.91 (-0.51%) ▼|AMZN253.54-3.24 (-1.26%) ▼|AVGO344.72-17.27 (-4.77%) ▼|AXP327.78+3.09 (+0.95%) ▲|BA210.27-0.18 (-0.09%) ▼|BAC59.47-3.22 (-5.14%) ▼|BKNG175.35+1.43 (+0.82%) ▲|BLK1,065.60-14.05 (-1.30%) ▼|BMY64.10+0.46 (+0.72%) ▲|BNY157.66-5.00 (-3.07%) ▼|BRK-B514.95+4.58 (+0.90%) ▲|C136.18-2.64 (-1.90%) ▼|CAT784.00-34.57 (-4.22%) ▼|CL87.89+1.09 (+1.26%) ▲|CMCSA24.88-0.32 (-1.27%) ▼|COF206.68-1.62 (-0.78%) ▼|COP136.67-0.68 (-0.50%) ▼|COST918.91+14.14 (+1.56%) ▲|CRM259.43+11.71 (+4.73%) ▲|CSCO110.06-2.07 (-1.85%) ▼|CVS95.55+0.89 (+0.94%) ▲|CVX212.17-1.89 (-0.88%) ▼|DE681.46+5.72 (+0.85%) ▲|DHR203.25+3.11 (+1.55%) ▲|DIS108.59+2.04 (+1.91%) ▲|DUK119.02-0.40 (-0.34%) ▼|EMR148.30-3.89 (-2.56%) ▼|FDX312.57+1.80 (+0.58%) ▲|GD356.81+0.91 (+0.26%) ▲|GE317.56-6.10 (-1.88%) ▼|GEV874.76-82.51 (-8.62%) ▼|GILD146.41+2.69 (+1.87%) ▲|GM87.16+1.54 (+1.80%) ▲|GOOG345.71+10.26 (+3.06%) ▲|GOOGL349.39+10.89 (+3.22%) ▲|GS988.45-40.73 (-3.96%) ▼|HD310.87+2.13 (+0.69%) ▲|HON201.38-0.98 (-0.48%) ▼|IBM249.09+5.80 (+2.38%) ▲|INTC97.19-5.75 (-5.59%) ▼|INTU339.15+17.58 (+5.47%) ▲|ISRG377.94+8.79 (+2.38%) ▲|JNJ266.32+0.74 (+0.28%) ▲|JPM350.13-6.10 (-1.71%) ▼|KO89.35+1.06 (+1.20%) ▲|LIN464.41-1.81 (-0.39%) ▼|LLY1,138.28+22.58 (+2.02%) ▲|LMT529.38+5.19 (+0.99%) ▲|LOW198.17+1.35 (+0.69%) ▲|LRCX273.49-24.73 (-8.29%) ▼|MA574.42+5.23 (+0.92%) ▲|MCD257.49+4.96 (+1.96%) ▲|MDLZ62.39-0.05 (-0.08%) ▼|MDT93.80+2.84 (+3.12%) ▲|META665.60+17.57 (+2.71%) ▲|MMM162.02-2.95 (-1.79%) ▼|MO70.61+1.63 (+2.36%) ▲|MRK144.85+0.92 (+0.64%) ▲|MS206.58-7.80 (-3.64%) ▼|MSFT505.41+9.78 (+1.97%) ▲|MU924.03-51.23 (-5.25%) ▼|NEE81.63-0.68 (-0.83%) ▼|NFLX80.32+2.92 (+3.77%) ▲|NKE37.05+0.25 (+0.68%) ▲|NOW142.35+9.82 (+7.41%) ▲|NVDA210.96-7.33 (-3.36%) ▼|ORCL144.79-5.49 (-3.65%) ▼|PEP136.34+0.02 (+0.01%) ▲|PFE27.72+0.00 (+0.00%) ▲|PG146.13+0.86 (+0.59%) ▲|PLTR173.31+6.08 (+3.64%) ▲|PM194.86+3.80 (+1.99%) ▲|QCOM180.15-1.82 (-1.00%) ▼|RTX195.34-2.34 (-1.18%) ▼|SBUX99.07+0.33 (+0.33%) ▲|SCHW107.31+0.06 (+0.06%) ▲|SO87.00-0.17 (-0.20%) ▼|SPG204.97+0.14 (+0.07%) ▲|T26.51+0.45 (+1.73%) ▲|TMO613.62+3.80 (+0.62%) ▲|TMUS182.90+0.57 (+0.31%) ▲|TSLA358.97-6.47 (-1.77%) ▼|TXN263.42-5.28 (-1.97%) ▼|UBER72.63+0.96 (+1.34%) ▲|UNH383.55+6.78 (+1.80%) ▲|UNP285.08+0.68 (+0.24%) ▲|UPS102.46+2.18 (+2.17%) ▲|USB62.68-0.16 (-0.25%) ▼|V375.28+4.83 (+1.30%) ▲|VZ51.29+0.68 (+1.34%) ▲|WFC88.71-1.58 (-1.75%) ▼|WMT109.08+1.93 (+1.80%) ▲|XOM165.08-0.91 (-0.55%) ▼|AAPL333.08+0.81 (+0.24%) ▲|ABBV261.77+4.65 (+1.81%) ▲|ABT103.09+1.14 (+1.12%) ▲|ACN195.00+11.10 (+6.04%) ▲|ADBE265.60+13.37 (+5.30%) ▲|AMAT424.21-32.28 (-7.07%) ▼|AMD493.41-22.72 (-4.40%) ▼|AMGN381.50+4.15 (+1.10%) ▲|AMT176.94-0.91 (-0.51%) ▼|AMZN253.54-3.24 (-1.26%) ▼|AVGO344.72-17.27 (-4.77%) ▼|AXP327.78+3.09 (+0.95%) ▲|BA210.27-0.18 (-0.09%) ▼|BAC59.47-3.22 (-5.14%) ▼|BKNG175.35+1.43 (+0.82%) ▲|BLK1,065.60-14.05 (-1.30%) ▼|BMY64.10+0.46 (+0.72%) ▲|BNY157.66-5.00 (-3.07%) ▼|BRK-B514.95+4.58 (+0.90%) ▲|C136.18-2.64 (-1.90%) ▼|CAT784.00-34.57 (-4.22%) ▼|CL87.89+1.09 (+1.26%) ▲|CMCSA24.88-0.32 (-1.27%) ▼|COF206.68-1.62 (-0.78%) ▼|COP136.67-0.68 (-0.50%) ▼|COST918.91+14.14 (+1.56%) ▲|CRM259.43+11.71 (+4.73%) ▲|CSCO110.06-2.07 (-1.85%) ▼|CVS95.55+0.89 (+0.94%) ▲|CVX212.17-1.89 (-0.88%) ▼|DE681.46+5.72 (+0.85%) ▲|DHR203.25+3.11 (+1.55%) ▲|DIS108.59+2.04 (+1.91%) ▲|DUK119.02-0.40 (-0.34%) ▼|EMR148.30-3.89 (-2.56%) ▼|FDX312.57+1.80 (+0.58%) ▲|GD356.81+0.91 (+0.26%) ▲|GE317.56-6.10 (-1.88%) ▼|GEV874.76-82.51 (-8.62%) ▼|GILD146.41+2.69 (+1.87%) ▲|GM87.16+1.54 (+1.80%) ▲|GOOG345.71+10.26 (+3.06%) ▲|GOOGL349.39+10.89 (+3.22%) ▲|GS988.45-40.73 (-3.96%) ▼|HD310.87+2.13 (+0.69%) ▲|HON201.38-0.98 (-0.48%) ▼|IBM249.09+5.80 (+2.38%) ▲|INTC97.19-5.75 (-5.59%) ▼|INTU339.15+17.58 (+5.47%) ▲|ISRG377.94+8.79 (+2.38%) ▲|JNJ266.32+0.74 (+0.28%) ▲|JPM350.13-6.10 (-1.71%) ▼|KO89.35+1.06 (+1.20%) ▲|LIN464.41-1.81 (-0.39%) ▼|LLY1,138.28+22.58 (+2.02%) ▲|LMT529.38+5.19 (+0.99%) ▲|LOW198.17+1.35 (+0.69%) ▲|LRCX273.49-24.73 (-8.29%) ▼|MA574.42+5.23 (+0.92%) ▲|MCD257.49+4.96 (+1.96%) ▲|MDLZ62.39-0.05 (-0.08%) ▼|MDT93.80+2.84 (+3.12%) ▲|META665.60+17.57 (+2.71%) ▲|MMM162.02-2.95 (-1.79%) ▼|MO70.61+1.63 (+2.36%) ▲|MRK144.85+0.92 (+0.64%) ▲|MS206.58-7.80 (-3.64%) ▼|MSFT505.41+9.78 (+1.97%) ▲|MU924.03-51.23 (-5.25%) ▼|NEE81.63-0.68 (-0.83%) ▼|NFLX80.32+2.92 (+3.77%) ▲|NKE37.05+0.25 (+0.68%) ▲|NOW142.35+9.82 (+7.41%) ▲|NVDA210.96-7.33 (-3.36%) ▼|ORCL144.79-5.49 (-3.65%) ▼|PEP136.34+0.02 (+0.01%) ▲|PFE27.72+0.00 (+0.00%) ▲|PG146.13+0.86 (+0.59%) ▲|PLTR173.31+6.08 (+3.64%) ▲|PM194.86+3.80 (+1.99%) ▲|QCOM180.15-1.82 (-1.00%) ▼|RTX195.34-2.34 (-1.18%) ▼|SBUX99.07+0.33 (+0.33%) ▲|SCHW107.31+0.06 (+0.06%) ▲|SO87.00-0.17 (-0.20%) ▼|SPG204.97+0.14 (+0.07%) ▲|T26.51+0.45 (+1.73%) ▲|TMO613.62+3.80 (+0.62%) ▲|TMUS182.90+0.57 (+0.31%) ▲|TSLA358.97-6.47 (-1.77%) ▼|TXN263.42-5.28 (-1.97%) ▼|UBER72.63+0.96 (+1.34%) ▲|UNH383.55+6.78 (+1.80%) ▲|UNP285.08+0.68 (+0.24%) ▲|UPS102.46+2.18 (+2.17%) ▲|USB62.68-0.16 (-0.25%) ▼|V375.28+4.83 (+1.30%) ▲|VZ51.29+0.68 (+1.34%) ▲|WFC88.71-1.58 (-1.75%) ▼|WMT109.08+1.93 (+1.80%) ▲|XOM165.08-0.91 (-0.55%) ▼|
20.9 C
New York
Tuesday, September 15, 2026

Tag: program

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the Taiwan Food and Drug Administration for the Treatment of Moderately to...

SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing...

FRONTERA ANNOUNCES SECOND QUARTER 2025 RESULTS

Recorded $455.2 million in Net Loss Mainly due to Non-Cash Impairment Charges Related to its Interest in the Corentyne License and Ecuadorian Assets Increased Total...

FRONTERA ANNOUNCES SECOND QUARTER 2025 RESULTS

Recorded $455.2 million in Net Loss Mainly due to Non-Cash Impairment Charges Related to its Interest in the Corentyne License and Ecuadorian Assets Increased Total...

Centrus Announces Pricing of Oversubscribed and Upsized Private Offering of Zero-Coupon Convertible Senior Notes Due 2032

BETHESDA, Md. , Aug. 13, 2025 /PRNewswire/ -- Centrus Energy Corp. (NYSE American: LEU) ("Centrus") today announced the pricing of $700 million aggregate principal amount of...

J SPORTS Teams Up with TVU to Boost Live Sports Coverage in Japan

Japan's Premier Sports Network Deploys Advanced Remote Production Technology for Enhanced Multi-Sport Broadcasting CUPERTINO, Calif., Aug. 14, 2025 /PRNewswire/ -- Japan's leading sports network J...

J SPORTS Teams Up with TVU to Boost Live Sports Coverage in Japan

Japan's Premier Sports Network Deploys Advanced Remote Production Technology for Enhanced Multi-Sport Broadcasting CUPERTINO, Calif., Aug. 14, 2025 /PRNewswire/ -- Japan's leading sports network J...

CCTV+: Deqing Steps Into the Global Travel Spotlight

BEIJING, Aug. 14, 2025 /PRNewswire/ -- From August 8 to 10, 2025, the "China Up Close Series: Zhejiang Tour" brought a contingent of nearly...

NativePath Liposomal Vitamin C: Urgent 2025 Consumer Warning on Why Most Vitamin C Pills May Fail — And the 3-in-1 Formula Positioned for Better...

Public interest in vitamin C has surged in 2025 as consumers search for cleaner, more effective options beyond standard pills. Across TikTok, Reddit, and wellness forums, questions are rising about ingredient sources, absorption rates, and the difference between synthetic ascorbic acid and real, whole-food vitamin C. NativePath Liposomal Vitamin C is positioned within this growing trend, featuring an amla-based 3-in-1 formula designed for nutrient integrity and advanced delivery. It reflects a broader shift toward transparency, clean sourcing, and solutions that align with evolving health and wellness priorities.
Public interest in vitamin C has surged in 2025 as consumers search for cleaner, more effective options beyond standard pills. Across TikTok, Reddit, and wellness forums, questions are rising about ingredient sources, absorption rates, and the difference between synthetic ascorbic acid and real, whole-food vitamin C. NativePath Liposomal Vitamin C is positioned within this growing trend, featuring an amla-based 3-in-1 formula designed for nutrient integrity and advanced delivery. It reflects a broader shift toward transparency, clean sourcing, and solutions that align with evolving health and wellness priorities.

Vertigenics – The Natural Vertigo Breakthrough Driving 2025 Interest in Balance and Brain Support Formulas

Public Interest in Natural Vertigo Support and Ingredient-First Balance Formulas Continues to Rise in 2025
Public Interest in Natural Vertigo Support and Ingredient-First Balance Formulas Continues to Rise in 2025

Providence St. Joseph Hospital Foundation Establishes First-Ever Endowed Chairs to Advance Excellence in Cardiac and Cancer Care

Donor generosity provides lasting support for physician leadership, innovation and patient care in Orange County ORANGE, Calif., Aug. 13, 2025 /PRNewswire/ -- Today Providence St....

LungExpand Pro Gains 2025 Spotlight as Plant-Based Daily Support Formula Amid Rising Public Interest in Breathing Comfort and Respiratory Wellness

Growing interest in natural respiratory support draws attention to ingredient-first formulations like LungExpand Pro, blending plant extracts and nutrients often discussed for breathing comfort and daily lung health.
Growing interest in natural respiratory support draws attention to ingredient-first formulations like LungExpand Pro, blending plant extracts and nutrients often discussed for breathing comfort and daily lung health.

CCTV+: Deqing Steps Into the Global Travel Spotlight

BEIJING, Aug. 14, 2025 /PRNewswire/ -- From August 8 to 10, 2025, the "China Up Close Series: Zhejiang Tour" brought a contingent of nearly 70...

CCTV+: Deqing Steps Into the Global Travel Spotlight

BEIJING, Aug. 13, 2025 /PRNewswire/ -- From August 8 to 10, 2025, the "China Up Close Series: Zhejiang Tour" brought a contingent of nearly 70...

CCTV+: Deqing Steps Into the Global Travel Spotlight

BEIJING, Aug. 13, 2025 /CNW/ -- From August 8 to 10, 2025, the "China Up Close Series: Zhejiang Tour" brought a contingent of nearly 70...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProgram